Comparisons between countries are essential for the control of COVID-19
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
On 6 May 2020, the UK Prime Minister Boris Johnson quoted statistician David Spiegelhalter, arguing that it was not appropriate to compare the COVID-19 death rate in the UK with other countries.1 Within a few hours, Spiegelhalter tweeted a request for the Prime Minister to stop quoting him and affirmed that ‘of course we should now use other countries to try and learn why our numbers are high’.2 The issue was that, although it is difficult to reliably compare COVID-19 population fatality rates between countries, it is also quite clear that some countries (e.g. UK, USA, Italy, Spain, Belgium, France) have markedly higher burdens of COVID-19 mortality than others (e.g. New Zealand, Australia, Singapore, South Korea, Germany). Although one could not say definitively that the UK was the worst in the world, it was performing worse than some countries which had tried alternative control strategies, and there are things that we can learn from that contrast. Indeed, epidemiology is built on the idea of studying differences between populations. Much of what we have learnt about the causes of disease has had its origins in comparisons of countries.3,4 For example, in the 1950s, it was realiz ed that colorectal cancer risks were high in Europe and low in Africa, possibly due to dietary differences in fibre from fruit and vegetable intake. Similarly, liver cancer was common in Asia, which eventually provided a link to hepatitis B. International differences in cervical cancer incidence and mortality suggested an infectious cause, later established as human papillomavirus (HPV). COVID-19 is different. The causative agent, SARS-CoV-2, is clear; the task is to learn how to best block the virus’s transmission and to prevent infections from progressing to severe disease and death. As the pandemic unfolds, there are numerous natural experiments in progress, as countries adopt different approaches. Although international comparisons are often disparaged because of different data quality and fears of the ‘ecological fallacy’, if done carefully they can play a major role in our learning what works best for controlling COVID-19.3 Furthermore, these natural experiments are yielding clear results within weeks or months (e.g. on the success of the Asian approaches). Thus, there needs to be more thoughtful and thorough analyses of country differences, done by experienced epidemiologists, as it is probably the most important and most valid evidence for informing COVID-19 policy in real time. And after all, what is the alternative? It is impossible or unethical to randomize a lockdown, or other aspects of physical distancing. There could be trials of intensive population testing,5 or prophylactic treatment of household contacts, but few have been launched to date. And all the time, the COVID-19-clock ticks relentlessly on, accumulating more deaths and more survivors with debilitating long-term health problems. Perhaps the biggest global difference has been the approach taken to the timing and intensity of testing and social distancing. Learning from their experiences of the coronavirus that causes SARS,6 governments in Asia (e.g. China, Hong Kong, Taiwan, Singapore, South Korea), soon followed by Australia and New Zealand (which is the only country to publish an elimination strategy7) took action early and decisively. There are differences across Asian countries, with most favouring rapid lockdowns although South Korea, for example, quickly mobilized intensive mass testing and contact tracing without the need for a full-scale lockdown; Taiwan also avoided the need for a lockdown and has achieved some of the lowest population infection rates recorded.8 In contrast, many European and North American countries were ready (more or less) to tackle pandemic influenza, but were not prepared for a coronavirus pandemic, even though the possibility of such a pandemic had been often discussed. Many countries took action too late and/or indecisively (with important exceptions such as Greece and Germany). They lost critical time, and the delays to action have cost lives. As the virus now spreads across nations in South America and Africa, the lessons from these differences in response take on even greater importance. However, appropriate inter-country comparisons are not going to be easy. Sweden has been an outlier in its relaxed approach to lockdowns. But who should Sweden be compared with? The population fatality rate in the UK (472 per million on 11 May 2020) is, at this time, higher than Sweden (322); but maybe Sweden, as a Scandinavian country with some ‘innate physical distancing’ and a different socioeconomic structure, is more comparable to Denmark (92), Norway (40), Finland (49) or even Australia and New Zealand (4). The comparisons are not helped by major differences in case definitions and quality—for example, the death rate in Belgium is among the highest in the world, but likely because it includes suspected COVID-19 deaths in the total
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing
Wang, C. J., Ng, C. Y., & Brook, R. H. (2020) · JAMA · doi:10.1001/jama.2020.3151 · Cited by 1,391
Banerjee, A., Pasea, L., Harris, S., Gonzalez-Izquierdo, A., Torralbo, A., Shallcross, L., Noursadeghi, M., Pillay, D., Sebire, N., Holmes, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30854-0 · Cited by 518
Research works printed but not linked: 20
- Spiegelhalter, 2020, Coronavirus deaths: how does Britain compare with other countries?, The Guardian
- Spiegelhalter, 2020, Author of Guardian article on death tolls asks UK government to stop using it, The Guardian
- Morris, 1957, Uses of Epidemiology
- Saracci, 2015, International Agency for Research on Cancer: the First Fifty Years -1965–2015
- Peto, 2020, Universal weekly testing as the UK COVID-19 lockdown exit strategy, Lancet, 395, 1420, 10.1016/S0140-6736(20)30936-3 · DOI
- Wilder-Smith, 2020, Can we contain the COVID-19 outbreak with the same measures as for SARS?, Lancet Infect Dis, 20, e102, 10.1016/S1473-3099(20)30129-8 · DOI · Paper page
- Baker, 2020, New Zealand’s elimination strategy for the COVID-19 pandemic and what is required to make it work, N Z Med J, 133, 10
- Pearce, 2020, Accurate statistics on Covid-19 are essential for policy guidance and decisions, Am J Public Health, 10.2105/AJPH.2020.305708. [Epub ahead of print.] · DOI
- Banerjee, 2020, Estimating excess 1-year mortality from COVID-19 according to underlying conditions and age in England: a rapid analysis using NHS health records in 3.8 million adults, MedRxiv, 10.1101/2020.03.22.20040287 · doi:10.1101/2020.03.22.20040287
- Robinson, 2020, The truth about Sweden and its COVID 19 coronavirus choices, New Zealand Herald
- Hanlon, 2020, COVID-19–exploring the implications of long-term condition type and extent of multimorbidity on years of life lost: a modelling study, Wellcome Open Res, 5, 75, 10.12688/wellcomeopenres.15849.1 · DOI · Paper page
- 2020, Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)
- Pearce, 2008, Epidemiology in Latin America: an opportunity for a global dialogue, J Epidemiol Community Health, 62, 762, 10.1136/jech.2008.078659 · DOI
- Pearce, 2012, Global epidemiology: the importance of international comparisons and collaborations, Open Access Epidemiol, 1, 15
- Hunter, 2020, Covid-19 and the stiff upper lip—the pandemic response in the United Kingdom, N Engl J Med, 382, e31, 10.1056/NEJMp2005755 · DOI · Paper page
- Caplin, 2017, International collaboration for the epidemiology of eGFR in low and middle income populations: Rationale and core protocol for the Disadvantaged populations eGFR epidemiology study (DEGREE), BMC Nephrol, 18, 1, 10.1186/s12882-016-0417-1 · DOI
- Ellwood, 2017, The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors, Eur Respir J, 49, 1601605, 10.1183/13993003.01605-2016 · DOI · Paper page
- 2020, Stepwise Approach to Surveillance
- Ruwanpathirana, 2019, Prevalence and risk factors for impaired kidney function in the district of Anaradhapura, Sri Lanka, BMC Public Health, 19, 763, 10.1186/s12889-019-7117-2 · doi:10.1186/s12889-019-7117-2
- Vandenbroucke, 2018, From ideas to studies: how to get ideas and sharpen them into research questions, Clinic Epidemiol, 10, 253, 10.2147/CLEP.S142940 · DOI
Cited by
Kontis, V., Bennett, J. E., Rashid, T., Parks, R. M., Pearson-Stuttard, J., Guillot, M., Asaria, P., Zhou, B., Battaglini, M., Corsetti, G., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1112-0 · Cited by 410
Excess mortality: the gold standard in measuring the impact of COVID-19 worldwide?
Beaney, T., Clarke, J. M., Jain, V., Golestaneh, A. K., Lyons, G., Salman, D., & Majeed, A. (2020) · Journal of the Royal Society of Medicine · doi:10.1177/0141076820956802 · Cited by 370
Galanis, P., Vraka, I., Fragkou, D., Bilali, A., & Kaitelidou, D. (2021) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.11.008 · Cited by 333
How families matter for health inequality during the COVID‐19 pandemic
Thomeer, M. B., Yahirun, J., & Colón‐López, A. (2020) · Journal of Family Theory & Review · doi:10.1111/jftr.12398 · Cited by 33
Metadata
- Authors
- Pearce, N., Lawlor, D. A., & Brickley, E. B.
- Venue
- International Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-06-29
- Volume
- 49
- Issue
- 4
- Pages
- 1059-1062
- ISSN
- 0300-5771 (ISSN-L)
- 1464-3685
- OpenAlex
- W3037713833
- Cited by
- 108
- References
- 2
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- University of Bristol
- UK medical Research Council (MC_UU_00011/1-7)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.